Overview

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Status:
Withdrawn
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
Phase:
Phase 4
Details
Lead Sponsor:
Alto Neuroscience
Treatments:
Bupropion
Duloxetine Hydrochloride